There’s a reason why this market’s so hard to kill — the rotations are endless and they are positive! Two weeks ago, you couldn’t give away the drug stocks. Now they are all things of beauty.
Category: Allergan
Allergan: Cramer’s Top Takeaways
Did you miss last night’s “Mad Money” on CNBC ? If so, here are some of Jim Cramer’s top takeaways. In his third and final “Executive Decision” segment, Cramer spoke with Brent Saunders, chairman and CEO of Allergan , which today reported a 14-cents-a-share earnings beat on a 7% rise in revenues, but still trades at just 15 times earnings.
California Sues Teva, Allergan for Allegedly Blocking Generic Competition to Lidoderm
The state of California has filed a civil suit against units of drugmakers Teva and Allergan , for allegedly obstructing generic competition to Lidoderm transdermal patches. The suit, filed in federal court in San Francisco, alleges a “pay-for-delay” deal between the companies and Endo Pharmaceuticals, which already had its Lidoderm product on the market and had made $825 million off of it in 2011.
Allergan, Starbucks, Citigroup: Doug Kass’ Views
Doug Kass shares his views every day on RealMoneyPro. Click here for a real-time look at his insights and musings.
Jobless Claims and Trimming GLD: Best of Kass
In highlights from this week’s trading diary and posts, Kass tells us about how he’s selling some Allergan shares and how he feels about the jobless claims. Doug Kass fills his blog on RealMoney every day with his up-to-the-minute reactions to what’s happening in the market and his legendary ahead-of-the-crowd ideas.
Saunders Paints Realistic Outlook for Allergan in 2017
Having fallen short of earnings expectations in its third quarter, Allergan says non-GAAP earnings per share should see double-digit growth in the year ahead. Allergan offered some color on its outlook for the year ahead on Thursday, and according to at least one company follower, the cautiousness of CEO Brent Saunders ought to be well received after the company widely missed its third quarter earnings target.
Starbucks, Allergan, Amazon: Doug Kass’ Views
Doug Kass shares his views every day on RealMoneyPro. Click here for a real-time look at his insights and musings.
Apple, Allergan, Twitter: Doug Kass’ Views
Doug Kass shares his thoughts on his latest ‘Best Ideas’ long and discusses how the market may have reached its Outer Limits. Doug Kass shares his views every day on RealMoneyPro.